Prenetics Completes Around $44 Million Equity Offering to Power IM8’s Global Expansion and Bitcoin Treasury Strategy

Posted on by

CHARLOTTE, N.C., Oct. 28, 2025 — Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a prominent health sciences firm, today confirmed the completion of its previously disclosed best efforts public offering (the “Offering”). This offering included (i) 2,722,642 Class A ordinary shares, with a par value of $0.0015 per share (the “Ordinary Shares,” and those sold in the Offering referred to as the “Shares”), (ii) warrants issued by the Company to acquire up to 2,722,642 Ordinary Shares (the “Class A Common Warrants”), and (iii) warrants issued by the Company to acquire up to 2,722,642 Ordinary Shares (the “Class B Common Warrants,” which, along with the Class A Common Warrants, are collectively termed the “Common Warrants”). The combined offering price for each Share and its accompanying Common Warrants was $16.08 (the “Offering Price”).

The Class A Common Warrants carry an exercise price of $24.12 per Ordinary Share, which represents a 50% premium over the Offering Price. The Class B Common Warrants have an exercise price of $32.16 per Ordinary Share, equating to a 100% premium over the Offering Price. All Common Warrants become immediately exercisable upon their issuance and remain valid for a period of five years from that date.

The gross proceeds generated for the Company from this Offering totaled approximately $44.0 million, prior to accounting for placement agent fees and other offering expenses payable by the Company. This amount reflects the final proceeds from the transaction, a slight adjustment from the approximately $48.0 million announced earlier. Prenetics intends to allocate these proceeds towards the worldwide expansion of IM8, propelled by its remarkable growth, and for the planned strategic accumulation of Bitcoin (BTC) as part of its pioneering dual health and wealth strategy. The Company itself issued all the Shares and accompanying Common Warrants.

Dominari Securities LLC (“Dominari”) functioned as the exclusive placement agent for the Offering. Reed Smith LLP provided legal counsel to the Company, while Sichenzia Ross Ference Carmel LLP served as counsel to Dominari.

The Company offered these securities through an amended shelf registration statement on Form F-3 (No. 333-288824), which included a base prospectus and was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on September 11, 2025. A final prospectus supplement and its corresponding base prospectus concerning this public offering have been filed with the SEC and can be accessed on the SEC’s official website at http://www.sec.gov. Individuals can also request copies of the final prospectus supplement and the accompanying prospectus for the offering by contacting Dominari Securities LLC, Attention: Syndicate Department, located at 725 5th Ave 23 Floor, New York, NY 10022, via email at info@dominarisecurities.com, or by calling (212) 393-4500.

This press release should not be interpreted as an offer to sell or a request for an offer to purchase these securities. Furthermore, no sale of these securities will occur in any state or jurisdiction where such an offer, solicitation, or sale would violate securities laws requiring prior registration or qualification. Any actual offer, if made, will exclusively be conducted through the prospectus supplement and its accompanying prospectus, which are part of the effective registration statement.

About Prenetics

Prenetics (NASDAQ: PRE) stands as a prominent health sciences firm, aiming to reshape the future of wellness and longevity with IM8. This flagship consumer brand, co-founded alongside David Beckham and endorsed by World No. 1 and four-time Grand Slam champion Aryna Sabalenka, has emerged as the fastest-expanding supplement brand worldwide. It achieved $100 million in annual recurring revenue within merely 11 months of its introduction, marking the quickest growth ever documented in the global supplements industry, even surpassing the pace of today’s top AI startups.

As the inaugural consumer health company to institute a Bitcoin Treasury, Prenetics remains at the forefront of combining health innovation with digital assets. The company acquires 1 Bitcoin daily, accumulating a total of 275 BTC as of October 27, 2025.

Forward-Looking Statements

This press release includes forward-looking statements. These assertions are made in accordance with the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements are recognizable by terms like “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” and similar expressions. Prenetics may also issue written or verbal forward-looking statements in its regular reports to the SEC, its annual shareholder report, other press releases and written documents, and in oral communications by its executives, directors, or personnel to external parties. Any statements that are not historical facts, including those concerning Prenetics’ convictions and outlook, are considered forward-looking statements. These statements inherently carry risks and uncertainties. Various elements could lead actual outcomes to differ substantially from those mentioned in any forward-looking statement. These include, but are not limited to: the Company’s capacity to successfully secure adequate capital on acceptable terms or at all; its ability to satisfy all conditions of the Offering and finalize it; its capability to implement its new Bitcoin treasury strategy; the market fluctuations of Bitcoin; its capacity to manage its expansion and growth; its ability to contend within the intensely competitive consumer health sector; and additional risks and uncertainties. More comprehensive details regarding these and other risks are provided in Prenetics’ submissions to the SEC. All data presented in this press release is current as of its publication date, and Prenetics disclaims any duty to revise or update any forward-looking statement, except as mandated by relevant law.

Investor Relations Contact:
investors@prenetics.com 
PRE@mzgroup.us
Angela Cheung
Investor Relations / Corporate Finance 
angela.hm.cheung@prenetics.com